Sign in or create an account to add this stock to your watchlist.
About Smith & Nephew (NYSE:SNN)
Smith & Nephew plc designs, develops, and sells medical devices worldwide. The company offers sports medicine joint repair products for surgeons, including an array of instruments, technologies, and implants necessary to perform minimally invasive surgery of the joints, such as the repair of soft tissue injuries and degenerative conditions of the knee, hip, and shoulder. It also provides arthroscopic enabling technologies for healthcare providers comprising fluid management equipment for surgical access, high definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue. In addition, the company offers trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; robotics-assisted surgery, various products, and technologies to assist in surgical treatment of the ear, nose, and throat; knee implant products for specialized knee replacement procedures; and hip implant products for the reconstruction of hip joints. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, including biologics and other bioactive technologies for debridement and dermal repair/regeneration; and advanced wound devices, such as traditional and single-use negative pressure wound therapy and hydrosurgery systems. The company primarily serves the providers of medical and surgical treatments and services. Smith & Nephew plc was founded in 1856 and is headquartered in London, the United Kingdom.
Industry, Sector and Symbol
Industry Surgical appliances & supplies
Sub-IndustryN/A
SectorMedical
SymbolNYSE:SNN
CUSIPN/A
Phone44-20-7401-7646
Debt
Debt-to-Equity Ratio0.31
Current Ratio2.03
Quick Ratio1.06
Price-To-Earnings
Trailing P/E Ratio18.91
Forward P/E Ratio18.52
P/E Growth2.05
Sales & Book Value
Annual Sales$4.77 billion
Price / Sales3.30
Cash Flow$2.9164 per share
Price / Cash12.32
Book Value$10.61 per share
Price / Book3.39
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A
Miscellaneous
Employees15,644
Outstanding Shares437,360,000
Smith & Nephew (NYSE:SNN) Frequently Asked Questions
What is Smith & Nephew's stock symbol?
Smith & Nephew trades on the New York Stock Exchange (NYSE) under the ticker symbol "SNN."
How often does Smith & Nephew pay dividends? What is the dividend yield for Smith & Nephew?
Smith & Nephew announced a None dividend on Wednesday, February 14th. Investors of record on Friday, April 6th will be paid a dividend of $0.444 per share on Wednesday, May 9th. The ex-dividend date of this dividend is Thursday, April 5th. View Smith & Nephew's Dividend History.
How were Smith & Nephew's earnings last quarter?
Smith & Nephew plc (NYSE:SNN) issued its quarterly earnings data on Monday, November, 17th. The medical equipment provider reported $0.98 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $0.39 by $0.59. View Smith & Nephew's Earnings History.
What price target have analysts set for SNN?
6 Wall Street analysts have issued 1 year price targets for Smith & Nephew's stock. Their forecasts range from $45.00 to $45.00. On average, they anticipate Smith & Nephew's share price to reach $45.00 in the next twelve months. View Analyst Ratings for Smith & Nephew.
What are Wall Street analysts saying about Smith & Nephew stock?
Here are some recent quotes from research analysts about Smith & Nephew stock:
- 1. According to Zacks Investment Research, "Smith & Nephew is a global medical device company. The company markets clinically superior products, principally in orthopaedics, endoscopy and wound management to deliver cost-effective solutions, significant physician advantage and real patient benefits. A continuous process of supplying new and innovative products is supported by substantial R&D investment to deliver new levels of healing to patients throughout the world " (4/17/2018)
- 2. Canaccord Genuity analysts commented, "We reiterate our BUY rating and $45 PT following Q4/17 sales results. Sales in the quarter were supported by strong global knee sales driven by above- market growth of Journey II in the US and Anthem in emerging markets. In recon we also highlight encouraging early momentum for Navio with management noting a ~50% increase in system sales, 500 surgeons trained in the US, and Navio accounts showing 2x growth in knees. While still early (2017 was the first full year of TKA launch) strong momentum in knees/Navio is encouraging given knees represent ~20% of overall revenue mix on a historical basis. Guidance came in a bit light relative to expectations — something we view as a conservative move given the pending CEO change. In sum, we reiterate our thesis that SNN is positioned to surprise investors in 2018 with a product portfolio capable of delivering accelerating growth and upside to profitability metrics." (2/8/2018)
Who are some of Smith & Nephew's key competitors?
Some companies that are related to Smith & Nephew include Intuitive Surgical (ISRG), Edwards Lifesciences (EW), Align Technology (ALGN), Zimmer Biomet (ZBH), Coloplast (CLPBY), William Demant (WILYY), STERIS (STE), Inogen (INGN), Mine Safety Appliances (MSA), Wright Medical Group (WMGI), Halyard Health (HYH), Consort Medical (CSRMY), Invacare (IVC), Sientra (SIEN) and RTI Surgical (RTIX).
Who are Smith & Nephew's key executives?
Smith & Nephew's management team includes the folowing people:
- Mr. Graham Timothy Baker, CFO & Exec. Director (Age 50)
- Mr. Namal Nawana, CEO & Exec. Director (Age 47)
- Mr. Matthew R. Stober, Pres of Global Operations (Age 50)
- Mr. Arjun Rajaratnam, Chief Compliance Officer
- Ms. Catheryn O'Rourke, Chief Legal Officer (Age 45)
Has Smith & Nephew been receiving favorable news coverage?
News articles about SNN stock have trended somewhat positive on Monday, according to Accern Sentiment. Accern identifies negative and positive press coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Smith & Nephew earned a media sentiment score of 0.11 on Accern's scale. They also gave media stories about the medical equipment provider an impact score of 46.76 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the near future.
Who are Smith & Nephew's major shareholders?
Smith & Nephew's stock is owned by many different of institutional and retail investors. Top institutional investors include Fiduciary Management Inc. WI (1.61%), Fisher Asset Management LLC (0.48%), Summit Trail Advisors LLC (0.31%), Millennium Management LLC (0.28%), Northern Trust Corp (0.16%) and US Bancorp DE (0.14%). View Institutional Ownership Trends for Smith & Nephew.
Which major investors are selling Smith & Nephew stock?
SNN stock was sold by a variety of institutional investors in the last quarter, including Highbridge Capital Management LLC, Dalton Greiner Hartman Maher & Co., Envestnet Asset Management Inc., Millennium Management LLC, Fisher Asset Management LLC, US Bancorp DE, Employees Retirement System of Texas and Liberty Mutual Group Asset Management Inc.. View Insider Buying and Selling for Smith & Nephew.
Which major investors are buying Smith & Nephew stock?
SNN stock was purchased by a variety of institutional investors in the last quarter, including Fiduciary Management Inc. WI, Summit Trail Advisors LLC, Sensato Investors LLC, JPMorgan Chase & Co., Point72 Asset Management L.P., Neuberger Berman Group LLC, Northern Trust Corp and Royal Bank of Canada. View Insider Buying and Selling for Smith & Nephew.
How do I buy shares of Smith & Nephew?
Shares of SNN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Smith & Nephew's stock price today?
One share of SNN stock can currently be purchased for approximately $35.93.
How big of a company is Smith & Nephew?
Smith & Nephew has a market capitalization of $15.68 billion and generates $4.77 billion in revenue each year. The medical equipment provider earns $767 million in net income (profit) each year or $1.90 on an earnings per share basis. Smith & Nephew employs 15,644 workers across the globe.
How can I contact Smith & Nephew?
Smith & Nephew's mailing address is 15 ADAM STREET, LONDON X0, WC2N 6LA. The medical equipment provider can be reached via phone at 44-20-7401-7646 or via email at [email protected]
MarketBeat Community Rating for Smith & Nephew (SNN)
MarketBeat's community ratings are surveys of what our community members think about Smith & Nephew and other stocks. Vote "Outperform" if you believe SNN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SNN will underperform the S&P 500 over the long term. You may vote once every thirty days.
Smith & Nephew (NYSE:SNN) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
6 Wall Street analysts have issued ratings and price targets for Smith & Nephew in the last 12 months. Their average twelve-month price target is $45.00, suggesting that the stock has a possible upside of 25.24%. The high price target for SNN is $45.00 and the low price target for SNN is $45.00. There are currently 1 sell rating, 1 hold rating and 4 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 2.50 | 2.80 | 2.50 | 2.50 |
| Ratings Breakdown: | 1 Sell Rating(s)
1 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
2 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
2 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $45.00 | $45.00 | $45.00 | $42.00 |
| Price Target Upside: | 25.24% upside | 16.07% upside | 31.89% upside | 11.08% upside |
Smith & Nephew (NYSE:SNN) Consensus Price Target History
Smith & Nephew (NYSE:SNN) Analyst Ratings History
Show:
(Data available from 5/21/2016 forward)
Smith & Nephew (NYSE:SNN) Dividend Information
Smith & Nephew pays an annual dividend of $0.68 per share, with a dividend yield of 1.89%. SNN's most recent none dividend payment was Wednesday, May 9. Smith & Nephew pays out 35.79% of its earnings out as a dividend.
| Most Recent Dividend: | 5/9/2018 |
| Annual Dividend: | $0.68 |
| Dividend Yield: | 1.89% |
| Dividend Growth: | -23.80% (3 Year Average) |
| Payout Ratio(s): | 35.79% (Trailing 12 Months of Earnings)
35.05% (Based on This Year's Estimates)
32.23% (Based on Next Year's Estimates)
23.32% (Based on Cash Flow)
|
Smith & Nephew (NYSE:SNN) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
| 2/14/2018 | None | $0.4440 | | 4/5/2018 | 4/6/2018 | 5/9/2018 |
| 8/28/2017 | semiannual | $0.2460 | 1.37% | 10/5/2017 | 10/6/2017 | 11/1/2017 |
| 2/28/2017 | semiannual | $0.37 | 2.42% | 3/29/2017 | 3/31/2017 | 5/10/2017 |
| 9/1/2016 | | $0.2360 | | 10/5/2016 | 10/7/2016 | 10/25/2016 |
| 2/8/2016 | | $0.37 | | 4/20/2016 | 4/22/2016 | 5/11/2016 |
| 4/9/2015 | semiannual | $0.3720 | 2.13% | 4/15/2015 | 4/17/2015 | 5/6/2015 |
| 9/9/2014 | semiannual | $0.55 | 1.28% | 10/22/2014 | 10/24/2014 | 11/12/2014 |
| 2/20/2014 | semiannual | $0.85 | 2.12% | 4/17/2014 | 4/22/2014 | 5/7/2014 |
| 8/28/2013 | special | $0.52 | 2.73% | 10/9/2013 | 10/11/2013 | 10/29/2013 |
| 3/11/2013 | semiannual | $0.81 | 2.97% | 4/17/2013 | 4/19/2013 | 5/8/2013 |
(Data available from 1/1/2013 forward)
Smith & Nephew (NYSE SNN) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 1.00%
Institutional Ownership Percentage: 8.66%
Smith & Nephew (NYSE SNN) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
(Data available from 1/1/2013 forward)
Smith & Nephew (NYSE SNN) News Headlines
| Source: |
|
Smith & Nephew (NYSE:SNN) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Smith & Nephew (NYSE:SNN) Income Statement, Balance Sheet and Cash Flow Statement
Smith & Nephew (NYSE SNN) Stock Chart for Monday, May, 21, 2018
Loading chart…
